Karyopharm Therapeutics Inc. (KPTI) stock
Close on Nov 9, 2026Market cap $1.16KP/E –Yield –
Karyopharm Therapeutics Inc. grew revenue 6.8% to $146.62M over the twelve months to Jun 30, 2026. Free cash flow was -$75.37M. At the latest close the market valued the company at $1.16K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.16K
- P/E ratio
- –
- Price to sales
- 0.00
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -6511248.19%
Fundamentals
- Revenue
- $146.62M
- Net income
- -$224.74M
- EPS, diluted
- -$17.93
- Free cash flow
- -$75.37M
- Book value per share
- -$11409.50
- Diluted shares
- 0M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $0.05
- Open
- $0.04
- Day's range
- $0.04 – $0.04
- Volume
- 23,722,490
- Average volume (20 days)
- 17,069,236
- Index membership
- Russell 2000 (since Jun 2026)
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 9, 2026. The S&P 500 is measured by the SPY fund.
| Period | KPTI | S&P 500 | Difference | KPTI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -93.4% | -3.3% | −90.1 pts | ||
| 3 months | -98.1% | -2.4% | −95.7 pts | ||
| Year to date | -99.5% | +11.2% | −110.7 pts | ||
| 1 year | -99.2% | +13.4% | −112.6 pts | ||
| 3 years | -99.6% | +79.9% | −179.5 pts | -84.3% | +21.6% |
| 5 years | -100.0% | +72.2% | −172.2 pts | -80.0% | +11.5% |
| 10 years | -100.0% | +307.3% | −407.3 pts | -55.8% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Karyopharm Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Results
- Update
About Karyopharm Therapeutics
Pharmaceutical Preparations
Karyopharm Therapeutics Inc. is a pharmaceutical company that focuses on the discovery, development, and commercialization of treatments such as Xpovio. Operating within the healthcare sector, the business develops product candidates and enters into commercial collaborations and licensing agreements with partner firms, including Menarini and Antengene Therapeutics. Through these arrangements, the company provides products and licenses its pharmaceutical assets to partners and customers across the industry.
Company profile, executives and historyKaryopharm Therapeutics stock: common questions
What is Karyopharm Therapeutics's stock price?
KPTI closed at $0.04 on Nov 9, 2026, down 20.00% on the day.
What is Karyopharm Therapeutics's market cap?
Karyopharm Therapeutics was worth $1.16K at the close on Nov 9, 2026: the share price times the diluted shares outstanding.
What is KPTI's P/E ratio?
Karyopharm Therapeutics lost money over fiscal 2025 (diluted EPS -$17.93), so it has no meaningful P/E ratio.
How much revenue does Karyopharm Therapeutics make?
Karyopharm Therapeutics reported revenue of $146.62M for the twelve months to Jun 30, 2026, up 6.8% from a year earlier.
Does Karyopharm Therapeutics pay a dividend?
No. Karyopharm Therapeutics has not paid a cash dividend over the last twelve months.
When does Karyopharm Therapeutics report earnings next?
Karyopharm Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has KPTI stock performed over the past year?
Including dividends, KPTI returned -99.2% over the past year, against +13.4% for the S&P 500.
Who are Karyopharm Therapeutics's competitors?
Companies most similar to Karyopharm Therapeutics by business, industry and size include LGND, AMRN, IDYA, TNGX, AKBA.
See a number that looks wrong?